TARGETING TREATMENT RESISTANT MELANOMA

Lumaros is currently developing the targeted therapy of choice in NRAS mutant melanoma

THE PROBLEM: NRAS MUTANT MELANOMA - A SUBTYPE WITH FEW TREATMENT OPTIONS

Laboratory Scientist

OUR SOLUTION: LURO-001 RE-SENSITIZES RESISTANT PATIENTS TO  THERAPY

Microscope